Trv Gp V LLC Makes New Investment in Septerna, Inc. $SEPN

Trv Gp V LLC purchased a new position in Septerna, Inc. (NASDAQ:SEPN) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 6,215,591 shares of the company’s stock, valued at approximately $208,160,143. Septerna comprises about 0.0% of Trv Gp V LLC’s holdings, making the stock its 2nd largest holding. Trv Gp V LLC owned about 13.79% of Septerna at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in SEPN. Group One Trading LLC increased its position in shares of Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after purchasing an additional 8,955 shares during the period. Global Retirement Partners LLC acquired a new position in Septerna in the 4th quarter valued at approximately $35,000. Russell Investments Group Ltd. acquired a new position in Septerna during the 3rd quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in Septerna during the fourth quarter worth about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Septerna in the fourth quarter worth $61,000.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SEPN. Stifel Nicolaus set a $49.00 target price on Septerna in a research report on Tuesday, August 11th. HC Wainwright raised their price target on Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. JPMorgan Chase & Co. raised their target price on shares of Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 19th. Wells Fargo & Company upped their price target on shares of Septerna from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Finally, Truist Financial increased their price target on Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Septerna has an average rating of “Moderate Buy” and a consensus target price of $52.44.

Septerna Price Performance

Shares of NASDAQ SEPN traded down $1.29 during midday trading on Friday, reaching $39.18. The company’s stock had a trading volume of 181,256 shares, compared to its average volume of 361,464. Septerna, Inc. has a 12-month low of $11.70 and a 12-month high of $51.10. The stock has a market capitalization of $1.83 billion, a P/E ratio of -72.56 and a beta of 2.29. The firm has a 50 day moving average price of $37.24 and a 200-day moving average price of $30.75.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. The firm had revenue of $26.75 million for the quarter, compared to the consensus estimate of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. On average, equities analysts predict that Septerna, Inc. will post -1.41 EPS for the current year.

Insiders Place Their Bets

In related news, insider Samira Shaikhly sold 2,178 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $35.18, for a total transaction of $76,622.04. Following the completion of the transaction, the insider directly owned 793 shares in the company, valued at $27,897.74. This represents a 73.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Daniel D. Long sold 3,334 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $34.47, for a total value of $114,922.98. Following the sale, the senior vice president owned 96,412 shares of the company’s stock, valued at approximately $3,323,321.64. The trade was a 3.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 61,030 shares of company stock worth $2,329,666 over the last three months. Company insiders own 5.80% of the company’s stock.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.